<DOC>
	<DOCNO>NCT01840046</DOCNO>
	<brief_summary>Alopecia areata autoimmune disease associate infiltration cluster differentiation 4 ( CD4 + ) cluster differentiation 8 ( CD8 ) + cell around hair follicle . One therapeutic approach inflammatory disease alopecia areata induction tolerance . This tolerance induction obtain stimulate regulatory T cell ( Treg ) . The low-dose interleukin-2 play central role development , expansion , regulation survival regulatory T cell CD4 + cluster differentiation 25 ( CD25 ) + forkhead box protein 3 ( FoxP3 ) . Recently , recombinant interleukin 2 ( IL2-R ) low dose show promising result two inflammatory disease ( GVHD vasculitis cryoglobulinemia secondary hepatitis C ) : clinical efficacy , increase population Treg blood excellent safety profile . We hypothesize administration IL2-R patient severe alopecia areata might allow regrowth via activation Treg thus induce regrowth air .</brief_summary>
	<brief_title>Evaluation Efficacy Tolerability Treatment With Interleukin-2 Severe Resistant Alopecia Areata</brief_title>
	<detailed_description />
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Age ≥ 18 year , 60 ≤ year . Male female Clinical diagnosis alopecia areata , Severe alopecia areata ( &gt; 50 % surface scalp reach ) Alopecia areata resistant least one systemic therapy : phototherapy ( UVB PUVA ) , methotrexate corticosteroid Signature inform consent authorization right image Effective contraception maintain duration study . Affiliation Social Security Pregnancy refusal contraception woman childbearing age , Refusal contraception men Local treatment ( corticosteroid , minoxidil ) systemic ( oral corticosteroid , methotrexate immunosuppressive agent ) less 2 month , Cancer autoimmune disease remission evolutionary Excessive alcohol intake ( 3 glass wine day drink per day ) HIV , hepatitis C virus , hepatitis B virus Patient renal / hepatic impairment , Patient shingle , chickenpox , herpes , tuberculosis , infectious disease scalable , respiratory failure ... Vulnerable person ( anyone younger , adult guardianship , deprive liberty ) Indication treatment IL2R Presenting indication Proleukin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>